NCT01968109 2026-04-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
Clinical Trials
78 trialsNCT06238687 2026-04-06
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Tasly Pharmaceutical Group Co., Ltd
Phase 1/2 Completed
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT05046171 2026-03-24
Decreasing Polypharmacy in Older Adults With Curable Cancers Trial
University of Rochester
Phase 1/2 Completed
NCT06056791 2026-02-27
CaRe
Inmune Bio, Inc.
Phase 1/2 Completed
NCT04260529 2026-01-29
CICILIA
Cytovation AS
Phase 1/2 Completed
NCT03872778 2026-01-28
NeoRay
Advanced Accelerator Applications
Phase 1/2 Completed
NCT05276284 2026-01-14
TEMPLE
Rigshospitalet, Denmark
Phase 1/2 Completed
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05383170 2025-11-28
Catalyst
Cytovation AS
Phase 1/2 Completed
NCT03363893 2025-11-12
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT03656718 2025-11-12
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05847686 2025-11-05
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
University of Washington
Phase 1/2 Completed
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01506973 2025-07-25
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT05159388 2025-07-08
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
Servier
Phase 1/2 Completed
NCT03520075 2025-07-03
Study of ASTX029 in Subjects With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1/2 Completed
NCT03733990 2025-04-02
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Faron Pharmaceuticals Ltd
Phase 1/2 Completed
NCT04761198 2025-03-17
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Mereo BioPharma
Phase 1/2 Completed
NCT04574583 2025-02-03
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04594005 2024-12-18
CDK4/6 Tumor, Abemaciclib, Paclitaxel
Yonsei University
Phase 1/2 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT01581840 2024-07-01
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT04669899 2024-04-09
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
Jounce Therapeutics, Inc.
Phase 1/2 Completed
NCT03190811 2024-02-07
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
Capital Medical University
Phase 1/2 Completed
NCT04288518 2023-10-23
Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.
Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase 1/2 Completed
NCT04534738 2023-09-22
DANICA
University of Rochester
Phase 1/2 Completed
NCT04538950 2023-09-13
PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
Mayo Clinic
Phase 1/2 Completed
NCT01813539 2023-08-09
A Study of ARGX-110 in Participants With Advanced Malignancies
OncoVerity, Inc.
Phase 1/2 Completed
NCT02501096 2023-07-20
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02904226 2023-07-03
ICONIC
Jounce Therapeutics, Inc.
Phase 1/2 Completed
NCT02895360 2023-05-10
Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Basilea Pharmaceutica
Phase 1/2 Completed
NCT01714739 2023-02-02
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01812603 2022-12-20
A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT01812616 2022-12-20
A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT01587040 2022-04-19
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Sanofi
Phase 1/2 Completed
NCT03695757 2021-07-06
Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG
Ajou University School of Medicine
Phase 1/2 Completed
NCT02941523 2021-06-02
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Noxopharm Limited
Phase 1/2 Completed
NCT02564367 2021-04-29
S-1 adjuvant
AIO-Studien-gGmbH
Phase 1/2 Completed
NCT02987829 2021-04-23
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT01271920 2020-12-08
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
Novartis
Phase 1/2 Completed
NCT01896856 2020-10-06
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00892424 2020-09-10
Sorafenib-RT Treatment for Liver Metastasis (SLIM)
University Health Network, Toronto
Phase 1/2 Completed
NCT00983619 2020-05-13
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
MedImmune LLC
Phase 1/2 Completed
NCT02929862 2019-09-25
Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Lycera Corp.
Phase 1/2 Completed
NCT02194426 2019-08-07
First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients
Molecular Partners AG
Phase 1/2 Completed
NCT03282643 2019-04-16
Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients
Capital Medical University
Phase 1/2 Completed
NCT00652080 2019-03-05
An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)
BPGbio
Phase 1/2 Completed
NCT00463060 2018-07-18
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed